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   Chronic inflammation is the basis of various chronic illnesses including cancer and 2 
vascular diseases. However, much has yet to be learned how inflammation becomes 3 
chronic. Although prostaglandins (PGs) are well established as mediators of acute 4 
inflammation, recent studies in experimental animals have provided evidence that they 5 
also function in transition to and maintenance of chronic inflammation. One role PGs 6 
play in such processes is amplification of cytokine signaling. As such, PGs can facilitate 7 
acquired immunity and induce long-lasting immune inflammation. PGs also contribute 8 
to chronic inflammation by making a positive feedback loop and/or by inducing 9 
chemokines and recruiting inflammatory cells to alternate active cell populations at 10 
affected sites. PGs also contribute to tissue remodeling as seen in angiogenesis and 11 
fibrosis. Although such roles of PGs should be verified in human diseases, these 12 
findings suggest that PG signaling is a promising therapeutic target of chronic 13 







Involvement of PGs in transition from acute inflammation to chronic 1 
inflammation?  2 
   Inflammation is triggered by various kinds of tissue insults, induces local reddening, 3 
heat, swelling, pain and fever, and mostly subsides in a few days. However, 4 
inflammation often persists and becomes chronic. Growing evidence now suggests 5 
involvement of chronic inflammatory processes in pathogenesis of a variety of diseases 6 
including cancer [1], metabolic syndrome [2] and vascular diseases [3]. In these 7 
disorders, abundant infiltration of inflammatory cells and expression of various 8 
pro-inflammatory molecules are found in affected tissues. Given that chronic diseases 9 
have a great impact on social health due to a large number of affected patients and a 10 
significant therapeutic cost, understanding mechanisms of transition to and maintenance 11 
of chronic inflammation is important. Potential mechanisms contributing to chronic 12 
inflammation include i) conversion of acute inflammation to long-lasting immune 13 
inflammation, ii) activation of a positive feedback loop by repetitive stimuli, iii) 14 
sustenance of inflammation by changing active cell populations in affected tissues, and 15 
finally iv) tissue remodeling. 16 
   Prostaglandins (PGs) including PGD2, PGE2, PGF, PGI and thromboxane (TX) 17 
A2 are a group of lipid mediators produced and released in response to various stimuli. 18 
4 
 
They are synthesized from arachidonic acid by sequential actions of cyclooxygenase 1 
(COX) and respective synthases, and exert their actions through a family of G 2 
protein-coupled receptors (GPCRs), prostaglandin D receptor (DP), EP1, EP2, EP3 and 3 
EP4 subtypes of prostaglandin E receptor, prostaglandin F receptor (FP), prostaglandin I 4 
receptor (IP) and thromboxane A receptor (TP), and one GPCR in a different family, 5 
CRTH2/DP2 [4]. Because COX is the target of aspirin-like non-steroidal 6 
anti-inflammatory drugs (NSAIDs) that effectively suppress various symptoms of acute 7 
inflammation, many symptoms of acute inflammation were presumed to be mediated by 8 
PGs. Indeed, recent studies using knockout mice deficient in each PG receptor and PG 9 
receptor type/subtype-specific agonists and antagonists have identified receptors and 10 
mechanisms responsible for PG-mediated inflammatory swelling, fever generation and 11 
hyperalgesia [4-6]. More intriguingly, these studies also suggest that PG signaling is 12 
involved in transition to and maintenance of chronic inflammation. Here we review 13 
experimental evidences to support such a hypothesis and discuss their therapeutic 14 
implications.  15 
 16 
PGs as a cytokine amplifier 17 
   Because COX-2 can be induced by lipopolysaccharide (LPS) and pro-inflammatory 18 
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cytokines such as interleukin (IL)-1 and IL-6, and COX-1 is constitutively expressed 1 
irrespectively of these stimuli, PGs are believed to be formed either independently or 2 
downstream of cytokines and innate immunity and elicit inflammatory symptoms. 3 
However, recent studies have revealed that PGs often work with cytokines and 4 
pathogen- or damage-associated molecular patterns (PAMPs and DAMPs) in various 5 
inflammatory settings and amplify cytokine- and PAMP/DAMP-signaling by enhancing 6 
expression of inflammation-related genes induced by these stimuli. For example, Honda 7 
et al. [7] reported interaction of PGI2-IP signaling and IL-1 in collagen-induced 8 
arthritis (CIA) in mice, a model of human rheumatoid arthritis. In this model, IP 9 
deficiency did not affect the incidence of arthritis but significantly reduced the extent of 10 
arthritis determined by inflammatory cell infiltration, synovial cell proliferation and 11 
bone destruction. Cytokine analysis revealed a marked reduction in the content of IL-6 12 
in arthritic paws of IP-deficient mice without affecting production of anti-collagen 13 
antibody. Treatment of cultured synovial fibroblasts with indomethacin in vitro 14 
significantly reduced the amount of IL-6 induced by IL-1, and this reduction was 15 
rescued by the addition of an exogenous IP agonist. Furthermore, microarray analysis 16 
revealed that approximately one-third of 400 genes induced by IL-1 in cultured 17 
synoviocytes were suppressed by the PG synthesis inhibitor indomethacin, and 18 
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expression of one hundred genes among them was restored by treatment with an IP 1 
agonist. The genes whose expression is amplified by IP signaling include; those 2 
involved in inflammation such as IL-6, IL-11, and CXCL7; those involved in cell 3 
proliferation such as various isoforms of fibroblast growth factor (FGF), vascular 4 
endothelial growth factor (VEGF) and hypoxia inducible factor 1 alpha (HIF1 and 5 
those involved in tissue remodeling such as receptor activator of nuclear factor kappa-B 6 
ligand (RANKL) and members of the a disintegrin and metalloproteinase with 7 
thrombospondin motifs (ADAMTS) family. It should be mentioned that PGI2 alone did 8 
not induce expression of these genes. Intriguingly, an approximately three-fold increase 9 
in expression of IL-1 receptor (IL1R1) was observed with the IP agonist treatment, 10 
suggesting that this may be the basis of IP-mediated amplification of IL-1signaling. 11 
Importance of PGI2 in development of arthritis was confirmed in another mouse model, 12 
autoantibody-driven K/BxN serum transfer arthritis [8]. Interestingly, PGI2 in this model 13 
almost solely derived from COX-1-catalyzed reaction. An example of PG-mediated 14 
amplification of PAMP/DAMP-signaling was reported by Oshima et al. [9], who 15 
examined interaction of PGE2-EP4 signaling and LPS. They stimulated the RAW264.7 16 
macrophage cell line with LPS, and examined the effects of a COX-2 inhibitor, 17 
celecoxib, and an EP4 antagonist, RQ-00015986/CJ-42794, on LPS-induced gene 18 
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expression. They found that celecoxib or RQ-00015986 significantly suppressed gene 1 
expression of COX-2, IL-1 and IL-6. These results support a role of PGE2-EP4 2 
signaling as an ‘amplifier’ of LPS signaling. Interestingly, the above treatment did not 3 
affect induction of microsomal prostaglandin E synthase-1 (mPGES-1) and tumor 4 
necrosis factor alpha (TNF- by LPS, suggesting selective modulation of gene 5 
expression. As described below in more detail, the role of PGs as a ‘cytokine amplifier’ 6 
was also demonstrated in induction of specific T helper subsets involved in immune 7 
inflammation [10]. These findings suggest that, in addition to their actions in acute 8 
inflammation, PGs are able to convert short-lived inflammatory responses to long-term 9 
gene-expression-dependent processes by facilitating actions of cytokines and/or innate 10 
immunity. Recognition of PGs as a ‘cytokine amplifier’ is conceptually important to 11 
understand their roles in chronic inflammation (Figure 1).       12 
 13 
PGs in acquired immunity and immune inflammation 14 
   Acquired immunity is initiated by processing and presentation to naïve T cells of 15 
antigen by dendritic cells (DCs), which are then differentiated to specific T cell subsets. 16 
The type of immune response is dependent on which T cell subset is induced to 17 
particular antigen. Two distinct subsets of helper T cells, Th1 and Th17, which are 18 
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characterized by production of interferon- (IFN-) and IL-17, respectively [11], are 1 
important cell populations that contribute to pathogenesis of various chronic 2 
autoimmune inflammatory diseases. Indeed, in human chronic inflammatory diseases 3 
such as multiple sclerosis and Crohn’s disease, elevation of IFN- and IL-17 and 4 
accumulation of these T cell subsets in affected organs (the brain of patients with 5 
multiple sclerosis and the gut of patients with Crohn’s disease) are reported [12-15]. 6 
Th1 differentiation is induced by IL-12 and facilitated by IFN-. Th17 differentiation 7 
and expansion are induced by TGF-/IL-6 and IL-23, respectively. Disruption of genes 8 
for these cytokines or their pharmacological inhibition suppressed disease development 9 
or progression in mouse models of the above diseases such as experimental autoimmune 10 
encephalomyelitis (EAE) and experimental colitis [16-18].  11 
   PGs have been traditionally regarded as immuno-suppressants. Indeed, 12 
PGE2/cAMP-mediated suppression of differentiation of Th1 cells has been repeatedly 13 
demonstrated in vitro [19, 20]. However, recent studies have revealed that, in contrast to 14 
traditional belief, PGs are involved in differentiation and expansion of Th1 and Th17 15 
cells (Figure 1). Yao et al. [10] revisited the action of PGE2 on Th1 differentiation. One 16 
plausible mechanism of inhibitory action of PGE2 and cAMP on T cell activation is 17 
lymphocyte-specific protein tyrosine kinase (LCK) phosphorylation by C-terminal Src 18 
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kinase, and this is antagonized by T cell receptor (TCR) stimulation. Yao and colleagues 1 
added increasing amounts of anti-CD28 to enhance TCR signaling and then examined 2 
effects of PGE2 on T cell differentiation under the Th1 skewing conditions. Intriguingly, 3 
under these conditions, PGE2 enhanced IL-12-mediated Th1 differentiation in a 4 
concentration-dependent manner from 1 nM. This action was mimicked by an EP2 or 5 
EP4 selective agonist and abolished in T cells deficient in EP2 and EP4, suggesting that 6 
with strengthened TCR stimulation, PGE2-EP2/EP4 signaling enhances rather than 7 
suppresses differentiation of T cells to the Th1 subset. They further extended their study 8 
and found that PGE2-EP2/4 signaling facilitates Th17 expansion induced by IL-23 via 9 
cAMP [10]. Chen et al. [21] used a selective EP4 antagonist, ER-819762, and also 10 
found these actions of PGE2-EP4 signaling on Th1 differentiation and Th17 expansion. 11 
Facilitation of IL-23-induced Th17 expansion by PGE2-EP2/4 signaling was also found 12 
in human memory T cells, in which the PGE2-cAMP pathway up-regulates expression 13 
of receptors for IL-23 and IL-1 and synergizes with these cytokines to drive ROR, 14 
IL-17, IL-17F, CCL20 and CCR6 expression [22-24]. Thus, PGE2 functions as a 15 
cytokine amplifier also in this case (Figure 1). Another site of expansion of Th17 cells 16 
by PGE2 is IL-23 production by DCs. Yao et al. [10] demonstrated that IL-23 17 
production from DCs stimulated with anti-CD40 antibody is enhanced by either PGE2 18 
10 
 
or an EP4 agonist, and surprisingly, the addition of an EP4 antagonist or indomethacin 1 
to this system almost totally suppressed IL-23 production, suggesting that endogenous 2 
PGE2 acts on EP4 and enhances IL-23 production from anti-CD40-stimulated DCs. 3 
Inhibitory action of EP4 antagonism on IL-23 production by DCs was also found by 4 
Chen et al. [21]. Furthermore, it was also shown that PGE2 in combination with 5 
Toll-like receptor ligands enhances the production of IL-23 p19 by DCs [25, 26]. In 6 
addition to these EP2/EP4-mediated immuno-stimulatory actions of PGE2, Nakajima et 7 
al. [27] found that PGI2-IP signaling also facilitates Th1 differentiation. Interestingly, 8 
they also reported that this signaling suppresses Th2 differentiation from naïve T cells 9 
from BALB/c mice under the Th2 skewing conditions (CD3/CD28 plus IL-4 10 
stimulation) [27]. Perhaps consistent with these findings, Takahashi et al. [28] found 11 
that loss of IP resulted in elevated IgE level and augmentation of allergic inflammation 12 
in mice with OVA-induced allergic asthma.  13 
   Consistent with its immune-stimulatory effects in vitro, PGE2-EP2/EP4 signaling 14 
appears to participate in antigen-specific Th1 and Th17 cell differentiation/expansion in 15 
vivo and is involved in disease progression of several immune inflammation models. 16 
Yao et al. [10] examined the role of PGE2-EP4 signaling in mouse contact 17 
hypersensitivity (CHS) and EAE. In these models, Th1 and Th17 cells are thought to be 18 
11 
 
involved in both induction and exacerbation of diseases. Results showed that treatment 1 
with an EP4 antagonist ameliorated both CHS and EAE [10]. Moreover, when 2 
researchers examined lymph node cells from the immunized mice, proliferation and 3 
production of IFN- and IL-17 in response to cognate antigen stimulation were 4 
significantly reduced in mice treated with the EP4 antagonist [10]. EP2 and EP4 appear 5 
to function redundantly in elicitation of EAE, because the EP4 antagonist suppresses T 6 
cell activation and disease progression more potently when administered to 7 
EP2-deficient mice than to wild-type mice [10]. Consistent with the 8 
immuno-stimulatory action of EP4, Chen et al. [21] examined effects of ER-819762 on 9 
CIA, and found that administration of this antagonist ameliorated progression of 10 
arthritis with concomitant suppression of Th1 and Th17 production by lymph node cells. 11 
These results suggest that PGE2-EP4 signaling functions in immunization processes, 12 
and blocking this signaling leads to suppression of Th1 differentiation and Th17 13 
expansion. Sheibanie et al. [29] used 2,4,6-trinitrobenzene sulfonic acid 14 
(TNBS)-induced colitis, an animal model of Crohn’s disease, and found that 15 
intraperitoneal (i.p.) administration of PGE2 or misoprostol, an EP3/EP4 agonist, 16 
exacerbated colitis and concomitantly increased expression of IL-23 p19, IL-17, IL-1, 17 
TNF-andIL-6 in the colon. They also reported that misoprostol administration 18 
12 
 
exacerbated CIA in mice, and increased expression of IL-23 p19 and IL-17 at the joint 1 
[30]. Taken together, these results suggest that PGE2-EP2/EP4 signaling facilitates Th1 2 
differentiation and Th17 expansion in vivo in various models of immune diseases. 3 
Consistent with this, recent genome-wide analysis identified PTGER4 (EP4) as a locus 4 
associated with Crohn’s disease [31] and multiple sclerosis [32]. In the former, risk 5 
SNPs in this locus are associated with increased EP4 expression [31]. 6 
 7 
  PGE2 in a positive feedback loop for inflammation 8 
   One possible mechanism for sustaining inflammation is a positive feedback loop to 9 
amplify the initial signal. Indeed, the presence of such a positive feedback loop 10 
involving PGs and its contribution to pathogenesis have been shown in animal models 11 
of chronic inflammatory diseases such as intracranial aneurysm (IA) and cancer. IA is a 12 
regional bulging of intracranial arteries (mostly at their bifurcation) and is histologically 13 
characterized by arterial wall degeneration, inflammatory cell infiltration and NF-B 14 
activation. IA is found in 1 to 5 % of the general population [33] and is a major cause of 15 
subarachnoid hemorrhage [34]. Because most IAs occur at bifurcation where high 16 
hemodynamic stress occurs, hemodynamic stress is believed to trigger IA formation. 17 
However, how hemodynamic stress leads to chronic inflammation remained unclear. 18 
13 
 
Aoki et al. [35] used an animal model of IA, and demonstrated that the chronic 1 
inflammatory response is induced by a positive feedback loop consisting of 2 
COX-2-PGE2-EP2-NF-B. They found induction of COX-2 expression in endothelial 3 
cells at the prospective site of aneurysm formation in vivo, which was mimicked in vitro 4 
in cultured endothelial cells subjected to shear stress. Celecoxib treatment suppressed 5 
IA formation, suggesting the importance of COX-2 in the pathogenesis of IA. They 6 
further found that EP2 is upregulated at the site of IA, and mice deficient in EP2 are 7 
selectively protected from IA. Furthermore, COX-2 inhibition suppressed EP2 8 
expression and EP2 deficiency suppressed COX-2 induction in IA walls. These two 9 
treatments both suppressed NF-B activation, and NF-B inhibition by decoy 10 
oligonucleotides suppressed COX-2 expression in the IA model. Because activated 11 
NF-B induces various inflammation-associated genes, including MCP-1 (CCL2), 12 
COX-2 inhibition and EP2 deficiency both reduced MCP-1 expression and suppressed 13 
macrophage infiltration. Thus, hemodynamic stress triggers COX-2 induction, and 14 
COX-2, PGE2, EP2 and NF-B make a positive feedback loop to amplify inflammatory 15 
signals (Figure 2). 16 
   Inflammation promotes tumourigenesis and is very often associated with cancer. 17 
One of the hallmarks of tumor-associated inflammation is expression of COX-2, though 18 
14 
 
COX-1 can also contribute to tumourigenesis [36]. Pharmacological inhibition and 1 
genetic deletion of COX isoforms prevent precancerous adenomas in humans and 2 
experimental animals and reduces colorectal cancer incidence in humans [37-39]. To 3 
identify the responsible PG receptor for COX-mediated tumourigenesis, Sonoshita et al. 4 
[40] made compound mutant mice of mice deficient in EP1, EP2 or EP3 and APC
716 
5 
mice, a model of human familial adenomatous polyposis. They found that loss of EP2 6 
selectively decreases the number and size of intestinal polyps in APC
716 
mice. They 7 
also demonstrated that EP2 is strongly induced and expressed in the same stromal 8 
region of polyps as COX-2, and that loss of EP2 almost completely suppresses COX-2 9 
induction in polyp tissues, suggesting a positive feedback loop between PGE2, EP2 and 10 
COX-2, as in IA. Furthermore, deletion of either COX-2 or EP2 suppresses induction of 11 
VEGF, angiopoetin-2 and laminin-2 in polyps. These results suggest that the 12 
COX-2-PGE2-EP2 loop functions in amplification of tumourigenesis-associated genes.  13 
Although the Sonoshita’s study did not identify involvement of NF-B in the positive 14 
feedback loop, its involvement was indicated recently in a separate study by Shin et al. 15 
[41]. They examined effects of nicotine on proliferation of the human gastric 16 
adenocarcinoma (AGS) cell line. Nicotine, a component of cigarette smoke, has been 17 
reported to promote tumor growth [42]. Shin et al. [41] analyzed microRNAs induced 18 
15 
 
by nicotine treatment of AGS cells and found upregulation of miR-16 and miR-21, 1 
which are known to be associated with gastric cancer. They further found that induction 2 
of these miRNAs is mediated by NF-B, and dependent on COX-2, EP2 and EP4. On 3 
the basis of these findings, the authors suggested that nicotine upregulates miR-16 and 4 
miR-21 in gastric cancer cells via EP2 and EP4 receptor-mediated NF-B 5 
transcriptional activation. Given that NF-B activity regulates COX-2 expression in 6 
many cases of tumourigenesis [43-45], these combined results suggest the presence of  7 
the COX-2-PGE2-EP2/4-NF-B loop that can amplify inflammation associated with 8 
tumourigenesis. However, the above three studies [43-45] were carried out in rather 9 
simplified model systems, one being polyposis and the other cultured cells, and did not 10 
address the role of inflammation directly. Therefore, detailed cross-talk between 11 
inflammation and tumors and the significance of PG signaling, EP2 in particular, should 12 
be examined in more suitable inflammation-associated colon cancer models such as 13 
azoxymethane-dextran sodium sulfate model [46]. 14 
 15 
PGs and recruitment of inflammatory cells 16 
   At inflammatory sites, abundant infiltration of inflammatory cells such as 17 
neutrophils, eosinophils and macrophages is seen, and recruitment of these cells is 18 
16 
 
mostly carried out by expression of chemokines. There is now substantial evidence that 1 
PGs are involved in induction of chemokines and resultant infiltration of inflammatory 2 
cells at the inflamed site (Figures 2 and 3). For example, as discussed above, the 3 
PGI2-IP signaling synergizes with IL-1 in CIA to augment expression of CXCL7, a 4 
chemokine for neutrophils, fibroblasts and endothelial cells [7].  In IA, one of the 5 
genes induced by the PGE2-EP2-NF-B pathway in endothelial cells is MCP-1, which 6 
recruits and activates macrophages to infiltrate the vessel wall [35]. Recruited 7 
macrophages then produce a variety of pathological molecules such as cytokines and 8 
proteinases [47, 48]. The contribution of MCP-1-mediated macrophage recruitment to 9 
the pathogenesis of IA was well defined by in vivo experiments using MCP-1-deficient 10 
mice, using a dominant negative form of MCP-1 or chlodronate liposome to deplete 11 
macrophages [47, 49]. Depletion of macrophages or the inhibition of MCP-1 12 
remarkably prevented IA formation through the suppression of macrophage-evoked 13 
inflammation. Thus, the PG signaling induces switching of active cell populations 14 
participating in inflammation of affected tissues. In a model of Helicobacter 15 
pylori-infected gastric tumor, Oshima et al. [9] found that bacterial colonization and 16 
PGE2 signaling through EP4 cooperatively induced the expression of MCP-1, and this 17 
was the major pathway for recruiting macrophages to gastric mucosa, which function as 18 
17 
 
tumor-associated macrophages to promote gastric tumors. In the Lewis lung tumor 1 
transplantation model, Katoh et al. [50] found COX-2 dependent CXCL12 (SDF1) 2 
expression in stromal fibroblasts surrounding the tumor, which is significantly 3 
attenuated in mice deficient either EP3 or EP4, and is reproduced by the addition of 4 
EP3- or EP4-selective agonists. CXCL12 is a chemokine for CD34
+
 bone marrow cells, 5 
T cells, B cells and DCs, and in the above study, the authors suggested that the cells 6 
recruited from bone marrow function for angiogenesis [50]. By contrast, Wang et al. 7 
[51] detected high levels of expression of CXCL1 in human colorectal cancers and 8 
adenomas of Apc
min
 mice. They further found that CXCL1 is induced by PGE2 in vitro 9 
in cultured colon cancer cell lines, and showed that some of the PGE2 effects on tumor 10 
growth are ameliorated by the addition of antibody to CXCL1 [51]. These findings 11 
combined together suggest that, under different inflammatory conditions, PGs can 12 
induce various chemokines, which then promote inflammation further (Figures 2 and 3). 13 
   In addition to induction of chemokine expression, one type of PG, PGD2 can 14 
directly recruit and activate Th2 lymphocytes and eosinophils by acting on CRTH2/DP2, 15 
which belongs to the chemokine receptor family [52], and this action is exerted in 16 
various allergic conditions [53].  Such CRTH2/DP2 actions on these inflammatory 17 
cells together with actions of DP1 possibly on sensitized airway epithelium [54] 18 
18 
 
contribute to elicitation of allergic inflammation in animal model of asthma.     1 
    2 
PGs and tissue remodeling 3 
  If inflammation does not subside, it often leads to tissue remodeling. Tissue 4 
remodeling includes tissue metaplasia, granulation, angiogenesis and fibrosis, and roles 5 
of PGs in these processes have been reported (Figure 4). PGs, depending on their type, 6 
involved tissues and contexts, either facilitate or suppress tissue remodeling. For 7 
example, in the ovalbumin (OVA)–induced allergic asthma model, various genes 8 
associated with tissue remodeling (including the ADAM family of tissue proteases and 9 
goblet cell metaplasia) are induced in the airway epithelium, and such induction is 10 
negatively modulated by PGE2-EP3 signaling [55]. Regulation of angiogenesis by PGs 11 
is found in chronic inflammation models such as CIA [7] and tumor-associated 12 
inflammation [40, 50, 51, 56-59] (Figure 4). Such signaling is mainly exerted by 13 
mesenchymal cells involved in inflammation; synovial cells in CIA and stromal 14 
fibroblasts in tumor-associated inflammation. Regulation of angiogenesis by PGs 15 
involves induction of both direct angiogenic factors such as VEGF and chemokines that 16 
recruit endothelial precursors to affected sites and induce tubular formation. For 17 
example, expression of VEGF by synovial fibroblasts is amplified by PGI2-IP signaling 18 
19 
 
[7], and PGE2 induces VEGF production from cultured cancer cell lines in vitro [56, 57]. 1 
In addition, upregulated expression of VEGF in cancer lesions and stromal tissues via 2 
EP2 or EP3 is suppressed through the inhibition of PG signaling in vivo [40, 58, 59]. 3 
PGs also regulate chemokine-mediated angiogenic pathways, such as CXCL12-CXCR4 4 
and CXCL1-CXCR2 signaling, which promote angiogenesis via recruiting endothelial 5 
precursors, and support tumourigenesis [50, 51].  6 
   Tissue fibrosis is characterized by fibroblast proliferation and excessive deposition 7 
of collagen and other extracellular matrix proteins, which exceeds normal repair 8 
processes for damaged tissues. Tissue fibrosis often represents the end stage of 9 
inflammation by disrupting tissue architecture and functions. PGs have been reported to 10 
exert both pro-fibrotic and anti-fibrotic actions (Figure 4). For example, Oga et al. [60] 11 
studied bleomycin-induced pulmonary fibrosis, a model of idiopathic pulmonary 12 
fibrosis of humans, and found that loss of FP attenuated pulmonary fibrosis without 13 
affecting inflammatory responses and with decreased collagen synthesis in vivo, 14 
indicating that PGF-FP signaling is involved in the fibrosis process itself. Consistent 15 
with this, the addition of PGF enhanced collagen synthesis in lung fibroblasts in vitro 16 
in a FP-dependent manner, and, intriguingly, in a manner additive to TGF-. These 17 
results suggest that PGF functions as a pro-fibrotic mediator in pulmonary fibrosis. 18 
20 
 
Indeed, levels of PGF were significantly elevated in bronchial alveolar lavage fluid of 1 
idiopathic pulmonary fibrosis patients [60]. By contrast, Lovgren et al. [61] found that 2 
loss of COX-2 (but not loss of mPGES-1) augmented fibrosis and worsened lung 3 
function in a bleomycin-induced pulmonary fibrosis model, which was mimicked by 4 
loss of IP but not that of either EP2 or EP4. On the basis of these findings, they 5 
suggested that PGI2-IP signaling protects against pulmonary fibrosis. A protective action 6 
of PGI2-IP signaling against fibrosis was also reported in heart, where IP and TP 7 
signaling appear to function antagonistically [62, 63]. These findings indicate 8 
importance of selective manipulation of signaling pathways of PGs to control tissue 9 
remodeling (Figure 4).      10 
  11 
Concluding remarks and future directions 12 
   In this review, we have discussed the roles of PGs in various animal models of 13 
chronic inflammation. Because the primary focus of this review is the role of PGs in 14 
transition to and maintenance of chronic inflammation, we have chosen recent finding 15 
pertinent to this role and discussed their implication. From the findings discussed here, 16 
it is now clear that PGs function as more than acute inflammatory mediators, and are 17 
involved in various aspects of chronic inflammation. However, in addition to the 18 
21 
 
pro-inflammatory actions described here, PGs also exert anti-inflammatory and 1 
immunoregulatory roles such as suppression of macrophage activation [64], 2 
tumor-induced immunosuppression [65, 66] and induction of regulatory T cells [67]. It 3 
is therefore important to clarify not only how PGs mediate chronic inflammation but 4 
also how PG-mediated anti-inflammatory circuit is integrated and, in some cases, down 5 
regulated in chronic inflammation. It is also important to examine whether PG signaling 6 
induce any epigenetic changes in the process of chronic inflammation, which may be 7 
very important to sustain the inflammatory state. These are future directions of 8 
inflammation research. We should also point out that, due to the space limit, we do not 9 
address interaction of PGs and other lipid mediators such as resolvins, which are 10 
proposed to function in termination of inflammation. This topic is discussed in a recent 11 
excellent review [68]. Finally, because animal models do not exactly recapitulate all 12 
aspects of human diseases, the findings discussed here must be validated in human 13 
diseases. Nonetheless, research in this area is therapeutically important, given the 14 
burden of chronic diseases in our society, and is promising, given that selective 15 
manipulation of receptors rather than general COX and mPGES inhibition apparently 16 
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Figure Legends 10 
Figure 1. The role of prostaglandin system as a cytokine amplifier. 11 
The contribution of prostaglandin system to the amplification of cytokine signaling is 12 
shown. Cytokines in blue are those whose signaling is amplified by the prostaglandin 13 
system. PGE2 synergistically induces IL-6/IL-1/COX-2 expression with LPS via EP4 14 
in macrophages (red dashed box at upper left) [9]. PGE2 also promotes the 15 
differentiation of Th1 from naïve T cells synergistically with IL-12 via EP2/EP4 (red 16 
dashed box at upper right) [10]. PGE2 stimulates dendritic cells (DCs) and promotes 17 
IL-23 production synergistically with CD40 and toll-like receptor (TLR) signaling. 18 
PGE2 then enhances the expansion of Th17 cells with IL-23 (red dashed box at lower 19 
right) [10, 21, 25, 26]. PGI2 also induces pro-inflammatory cytokines such as IL-6 from 20 
synovial fibroblasts synergistically with IL-1(red dashed box at lower left ) [7]. 21 
 22 
Figure 2. The proposal mechanisms of chronicity of inflammation contributing to 23 
30 
 
intracranial aneurysm formation. 1 
Positive feedback loop consisting of COX-2-PGE2-EP2-NF-B and macrophage 2 
infiltration in arterial walls by NF-B-mediated MCP-1 expression contribute to the 3 
chronic inflammation responsible for intracranial aneurysm formation . 4 
 5 
Figure 3. The contribution of prostaglandin system to the recruitment of immune cells. 6 
PGE2 and PGI2 induce chemoattractants (MCP-1, CXCL12, CXCL7) resulting in the 7 
recruitment of inflammatory cells to affected sites. 8 
 9 
Figure 4. The contribution of prostaglandin system to tissue remodeling. 10 
Prostaglandin system promotes or suppresses tissue remodeling, including metaplasia, 11 
fibrosis and angiogenesis, in a context-dependent manner. Red or blue color indicates 12 
the contribution of prostaglandin system to the promotion or suppression of tissue 13 
remodeling, respectively.      14 
 15 
 16 




